News and reporting on cell-free DNA testing.
Formerly called OncoCell MDx, the Royal Oak, Michigan-based firm aims to complete a validation study for the prostate cancer risk assay within the next two months.
The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
